References
- Anderson SD, Shah NK, Yim J, Epstein BJ. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Ann. Pharmacother. 44(3), 524–537 (2010).
- James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 157(4), 599–605 (2009).
- Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
- Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value Health 16(4), 574–580 (2013).
- Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M; Group PHES. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur. Heart J. 34(3), 220–228 (2013).
- Euroqol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16(3), 199–208 (1990).
- Rabin R, Oemar M, Oppe M. EQ-5D-3L User Guide: Version 4. EuroQoL Group, Rotterdam, The Netherlands (2011).
- Goldsmith KA, Dyer MT, Schofield PM, Buxton MJ, Sharples LD. Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health Qual. Life Outcomes 7, 96 (2009).
- Testa MA, Simonson DC. Assessment of quality of life outcomes. N. Engl. J. Med. 334(13), 835–840 (1996).
- Euroqol Group’s International Task Force on Self-Reported Health. Measuring Self-Reported Population Health: An International Perspective based on EQ-5D. EuroQol Group, Rotterdam, The Netherlands (2004).
- Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynänen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int. J. Technol. Assess. Health Care 22(2), 235–241 (2006).
- Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health 12(8), 1194–1200 (2009).
- Brazier Je RD, Mavranezouli I, Tsuchiya A et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol. Assess. 16(32), 1–113 (2012).
- Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141( 2 Suppl.), e637S–e668S (2012).
- Carney RM, Freedland KE. Depression in patients with coronary heart disease. Am. J. Med. 121(11 Suppl. 2), S20–S27 (2008).
- Davidson KW, Bigger JT, Burg MM et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Intern. Med. 173(11), 997–1004 (2013).